The MACH Clinical Trials Committee aims to facilitate a community of practice in clinical trials across the MACH partners to increase efficiency and increase the number, quality, and impact of clinical trials performed within the MACH. It acts as a forum for effective communication between MACH partners, and between MACH and external stakeholders.
 
The committee will identify key priorities and recommend strategies to achieve these objectives, ensuring a comprehensive approach to advancing clinical trial initiatives.

The committee provides oversight of MACH node of the Health Studies Australian National Data Asset (HeSANDA) program and the Melbourne Centre for Clinical Trials (MCCT).

Chair

Professor Andrew Davidson

MACH SUPPORT

Renata Phyland

Email

Objectives: 

Strategic Advocacy and Government Relations:

  • Serve as a key strategic forum to engage with government and other bodies, increasing the profile and advocating for the advancement of clinical trials within the MACH partners and the broader sector.

Communication and Collaboration:

  • Act as a communication forum for clinical trial activity among MACH partners, fostering collaboration and information sharing.
  • Identify continuous improvement opportunities in clinical trial capabilities across and among MACH partners, developing strategies for optimisation of resources and expertise.

Streamlining Processes and Systems:

  • Provide leadership to input into initiatives to optimise the system for ethical and governance approval within the MACH network while aiming for efficient and standardised processes.

Capacity Building and Support Services:

  • Increase awareness to support services related to investigator-led trials.
  • Facilitate the sharing of resources across MACH partners, such as documents, standard operating procedures (SOPs), teaching materials, and training programs.

Oversight and Collaboration with MCCT:

  • Provide oversight of the Melbourne Centre for Clinical Trials (MCCT) together with the University of Melbourne, in accordance with the MCCT Terms of Reference.

Oversight of the MACH node of the Health Studies Australian National Data Asset (HeSANDA):

  • Provide oversight of the MACH node (led by the MISCH research Hub) of the Health Studies Australian National Data Asset (HeSANDA) program to build national infrastructure to support the sharing and reuse of health research data.

Policy Influence and Collaboration:

  • Work with Monash Partners, Western Alliance, and the Australian Health Research Alliance to influence clinical trial policy at the State and Federal levels, advocating for favourable policies and regulations.

 

Name: Affiliations: Bio:
Dr Andrew Brockway Doherty Clinical Trials Limited
Ms Linda Brown Safer Care Victoria
Professor Adam Deane Royal Melbourne Hospital
Professor Andrew Davidson Murdoch Children’s Research Institute, Royal Children’s Hospital
A/Professor Patty Chondros University of Melbourne
Dr Heidi Gaulke Austin Health
Mr Bill Karanatsios Western Health
Professor Lyndell Lim Centre for Eye Research Australia
Dr Megan Robertson St Vincent’s Hospital
Professor Mark Rosenthal Peter MacCallum Cancer Centre
Professor Julie Simpson University of Melbourne
Professor David Story Austin Health
Dr Jacqui Waterkeyn Royal Melbourne Hospital

Widening Access to clinical trials
Pursuit magazine, May 2021, Prof David Story, Prof Robyn Woodward-Kron, Prof John Hajek, Anna Parker, Dr Tuong Phan